Biolinq and Taisho Pharmaceutical Announce Strategic Collaboration and Exclusive License Agreement in Japan
Taisho Pharmaceutical Named Commercial Partner for Biolinq’s Novel Biowearable Technology
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Jun 23
Taisho Pharmaceutical Named Commercial Partner for Biolinq’s Novel Biowearable Technology
21 Jun 23
LODOCO Targets Residual Inflammation as an Underlying Cause of ASCVD and Can be Used Alone or in Combination…
20 Jun 23
The collaboration will focus on precision medicine tailored to individual needs to advance the personalised medicine and genomics…
20 Jun 23
CART-ddBCMA is a BCMA-specific CAR-modified T-cell therapy that uses the company’s BCMA-targeting binding domain for the treatment of…
20 Jun 23
The FDA advised the biopharmaceutical firm to proceed with late-stage clinical development based on the efficacious data and…
20 Jun 23
In studies, a 12-week course of WINLEVI therapy decreased both inflammatory and noninflammatory lesions and significantly enhanced the…
20 Jun 23
The device is intended for use in percutaneous transluminal angioplasty, following appropriate vessel preparation, for treating de novo…
20 Jun 23
SKYCovione is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for SARS-CoV-2
20 Jun 23
New Supplement Developed to Support Restful Sleep and a Healthy Gut Microbiome
19 Jun 23
Columvi (glofitamab-gxbm) is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and…